Indivior PLC (LON: INDV)
London
· Delayed Price · Currency is GBP · Price in GBX
960.00
-13.00 (-1.34%)
Jan 23, 2025, 2:39 PM BST
Indivior Revenue
Indivior had revenue of $307.00M USD in the quarter ending September 30, 2024, with 13.28% growth. This brings the company's revenue in the last twelve months to $1.18B, up 13.44% year-over-year. In the year 2023, Indivior had annual revenue of $1.09B with 21.31% growth.
Revenue (ttm)
$1.18B
Revenue Growth
+13.44%
P/S Ratio
1.49
Revenue / Employee
$1.02M
Employees
1,164
Market Cap
1.21B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.09B | 192.00M | 21.31% |
Dec 31, 2022 | 901.00M | 110.00M | 13.91% |
Dec 31, 2021 | 791.00M | 144.00M | 22.26% |
Dec 31, 2020 | 647.00M | -138.00M | -17.58% |
Dec 31, 2019 | 785.00M | -220.00M | -21.89% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Indivior News
- 5 days ago - Two Seas Capital LP Adjusts Position in Indivior PLC - GuruFocus
- 5 weeks ago - Indivior CFO steps down from board after discussions with Oaktree Capital - Seeking Alpha
- 5 weeks ago - BUSINESS LIVE: Wage growth accelerates; Britvic takeover cleared; Capita to cut more staff - This is Money
- 2 months ago - Indivior PLC (INDV) Trading 3.1% Higher on Nov 19 - GuruFocus
- 2 months ago - Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024 - PRNewsWire
- 2 months ago - SCOPIA CAPITAL MANAGEMENT LP Adjusts Stake in Indivior PLC - GuruFocus
- 2 months ago - Indivior jumps amid investor letter, takeover speculation (update) - Seeking Alpha
- 2 months ago - Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior - PRNewsWire